Real-world data demonstrating efficacy of cefiderocol in difficult-to-treat bacterial infections

New data from Japanese drugmaker Shionogi’s (TYO: 4507) largest European real-world evidence study of cefiderocol (PERSEUS), demonstrates strong efficacy in critically ill patients with difficult to treat carbapenem-resistant (CN) Gram-negative (GN) bacterial infections.

Cefiderocol, marketed under the brand names Fetcroja and Fetroja, provides coverage against the three critical priority pathogens, carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales, identified by the World Health Organization (WHO).

Presented by Shionogi at the 34th European Congress of Clinical Microbiology and Infectious Disease (ESCMID), the data from the PERSEUS study demonstrated that, in patients with GN infections the overall clinical success rate after treatment with cefiderocol was 84.3% and a 28-day all-cause mortality of 21.5%.